NCT01633541View on ClinicalTrials.gov

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 6, 2021

Study Completion Date

November 6, 2021

Conditions
Laryngeal Cancer
Interventions
DRUG

AT-101

Patients will receive AT-101 40 mg orally two times a day.

DRUG

Docetaxel

Docetaxel (Taxotere) 75 mg/m2

DRUG

Cisplatin

Cisplatin 100 mg/m2

DRUG

Carboplatin

Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT01633541 - Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer | Biotech Hunter | Biotech Hunter